Sugaya Takeshi, Takagi Tomohisa, Uchiyama Kazuhiko, Kajiwara-Kubota Mariko, Asaeda Kohei, Okumura Keita, Inaba Tohru, Naito Yuji, Itoh Yoshito
Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kamigyo-ku, Kyoto 602-8566, Japan.
Faculty of Clinical Laboratory, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kamigyo-ku, Kyoto 602-8566, Japan.
J Clin Biochem Nutr. 2023 Mar;72(2):183-188. doi: 10.3164/jcbn.22-60. Epub 2023 Jan 12.
Vaccination is an important strategy to reduce the infection rate and adverse events of coronavirus disease 2019 (COVID-19). However, the effect of COVID-19 vaccination for Japanese patients with inflammatory bowel disease (IBD) has not been fully elucidated. In the present study, we investigated the serum titer of neutralizing antibodies after COVID-19 vaccination in patients with IBD, treated with and without immunosuppressive therapy. The study consisted of 108 patients with IBD [76 with ulcerative colitis (UC) and 32 with Crohn's disease (CD)] from the gastroenterology outpatient clinic at the Hospital of the Kyoto Prefectural University of Medicine who underwent anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. The control group included 64 healthy subjects who received the anti-SARS-CoV-2 vaccine. When 10 AU/ml of neutralizing antibodies was used as cut-off value, the positive rates of neutralizing antibodies of patients with UC, patients with DC, and the control group were 97.3%, 84.3%, and 100%, respectively. The neutralizing antibody titer showed no difference between patients treated with and without immunosuppressive therapy. These results indicate that COVID-19 vaccination may be useful in patients with IBD, treated with or without immunosuppressive therapy.
接种疫苗是降低2019冠状病毒病（COVID-19）感染率和不良事件的重要策略。然而，COVID-19疫苗对日本炎症性肠病（IBD）患者的效果尚未完全阐明。在本研究中，我们调查了接受和未接受免疫抑制治疗的IBD患者接种COVID-19疫苗后中和抗体的血清滴度。该研究包括来自京都府立医科大学医院胃肠病门诊的108例IBD患者[76例溃疡性结肠炎（UC）患者和32例克罗恩病（CD）患者]，他们接受了抗严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗接种。对照组包括64名接受抗SARS-CoV-2疫苗接种的健康受试者。以10 AU/ml的中和抗体作为临界值时，UC患者、DC患者和对照组的中和抗体阳性率分别为97.3%、84.3%和100%。接受和未接受免疫抑制治疗的患者之间中和抗体滴度无差异。这些结果表明，无论是否接受免疫抑制治疗，COVID-19疫苗接种对IBD患者可能都是有用的。
